Monday, November 9, 2026

USD/EUR Bearish By 1% In The Last 21 Sessions

USD/EUR Bearish By 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.67% for the last 21 sessions. At 07:08 EST on Thursday, 6 July, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 1.897% up from its 52-week low and 12.374% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.19%, a negative 0.06%, and a positive 0.33%, respectively.

USD/EUR's highest amplitude of average volatility was 0.19% (last week), 0.32% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy remains on the defensive, below mid-144.00s on Japan intervention fears. According to FXStreet on Tuesday, 4 July, "The USD/JPY pair comes under some selling pressure on Tuesday and reverses a major part of the previous day's positive move back closer to the 145.00 psychological mark. ", "Speculations for a potential intervention by the Japanese government to curb any further sharp decline in the domestic currency turn out to be a key factor acting as a headwind for the USD/JPY pair. "
  • Usd/jpy technical analysis: the US holiday weakens the appetite of investors - 04 July 2023. According to DailyForex on Tuesday, 4 July, "The weakness of the Japanese yen has hurt many Japanese companies that depend on imports.USD/JPY Technical OutlookAccording to the performance on the daily chart below, the USD/JPY price is still in a strong bullish trend in the past few months.", "The USD/JPY currency pair also jumped after signs that the Japanese government will intervene if the Japanese currency continues to decline. "
  • Usd/jpy consolidates in a range around mid-144.00s, just below YTD peak. According to FXStreet on Wednesday, 5 July, "The USD/JPY pair continues with its struggle to gain any meaningful traction on Wednesday and oscillates in a narrow trading band around mid-144.00s through the Asian session. ", "Against the backdrop of the USD/JPY pair's recent rally from the June swing low, the range-bound price action witnessed over the past week or so might still be categorized as a bullish consolidation phase. "
  • Usd/jpy price analysis: grinds near 144.50 within weekly triangle, depicts cautious mood. According to FXStreet on Wednesday, 5 July, "With this, the USD/JPY pair remains sidelined within the weekly triangle, currently between 144.65 and 144.30.", "Though, an upward-sloping trend line from June 20 and the 200-Hour Moving Average (HMA), respectively near 144.20 and 144.10, quickly followed by the 144.00 round figure, can challenge the USD/JPY bears before giving them control."
  • Usd/jpy: A reversal in the trend would require market dynamics to change – OCBC. According to FXStreet on Tuesday, 4 July, "If USD/JPY trades volatile by another 2-3 JPY intra-day, then authorities could really act. ", "That said, such activities (jawboning, etc.) probably only serve to slow the pace of USD/JPY upticks especially if the uptrend remains intact."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com